Pharmacy Friday Pearls

MARCH 4, 2022

18 years Administration Oral Oral Oral PK/PD MOA: Nirmatrelvir – inhibitor of the SARS-CoV-2 main protease Prevents viral replicationRitonavir is a CYP3A inhibitor included to increase nirmatrelvir plasma levelsRitonavir alone has NO activity against SARS-CoV-2 Time to peak: Nirmatrelvir: 3 hrs & Ritonavir: 3.98 Introduction.

HIV Treatment and Prevention Agents 40

HIV Treatment and Prevention Agents Hospitals Packaging Immunization 40

PharmaShots

APRIL 25, 2023

This drug is currently in multiple P-IIa clinical trials and is being evaluated in combination with other antiviral agents for cHBV. ARO-AAT and ARO-APOC3 are among the highest-phase products developing under Arrowhead’s pipeline for the treatment of liver diseases. R&D Expenditure: $85.1M R&D Expenditure: $437.9M

HIV Treatment and Prevention Agents 40

HIV Treatment and Prevention Agents Packaging Immunization Vaccines 40

The Checkup by Singlecare

FEBRUARY 6, 2023

Pneumonia is often mild to moderate, requiring only outpatient treatment. Risk factors of pneumonia are age older than 65, chronic obstructive pulmonary disorder ( COPD ), HIV infection , weakened immune system and smoking. Pneumonia usually requires evaluation and treatment. Treatment depends on the cause.

HIV Treatment and Prevention Agents 52

HIV Treatment and Prevention Agents Vaccines Hospitals Immunization 52